glp-1-based therapy GLP-1 Medications – Community Education Q&A: Long-term success of GLP-1

GIPR antagonist, GIP(330)NH2, and GIP co-infusion in lean individuals prevented a fivefold increase in adipose tissue blood flow induced by GIP infusion alone ( Co-administration of triton-WR1339 infusion and D-Ala2-GIP injection 20 min following oil gavage in mice significantly increases TG accumulation in plasma at 60 and 90 min, and ApoB-48 levels at 90 min compared to PBS control (Hsieh et al., 2010), suggesting a role for GIP in plasma TG independent of triglyceride rich lipoprotein (TRL) clearance

[DOI] [PMC free article] [PubMed] [Google Scholar] 110.Ishibashi Y., Matsui T., Takeuchi M., Yamagishi S

[54].Drucker DJ, Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1, Cell Metab 27(4) (2018) 740756

Side Effects Semaglutide: Common Side Effects: Nausea Vomiting Diarrhoea Constipation Abdominal pain Less Common Side Effects: Headache Fatigue Dizziness Hypoglycaemia (especially in individuals with type 2 diabetes) Pancreatitis (rare but serious) Tirzepatide: Common Side Effects: Nausea Vomiting Diarrhea Constipation Abdominal pain Less Common Side Effects: Decreased appetite Dyspepsia (indigestion) Injection site reactions Hypoglycemia (more common when combined with insulin or sulfonylureas) Pancreatitis (rare but serious) Administration Semaglutide: Administered via injection

Reimbursement policies, pricing pressures, supply chain dynamics, and cultural attitudes to obesity are producing starkly different patterns of access across the worlds major markets